These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 26496700)
21. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979 [TBL] [Abstract][Full Text] [Related]
22. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Yeung CL; Ngo VN; Grohar PJ; Arnaldez FI; Asante A; Wan X; Khan J; Hewitt SM; Khanna C; Staudt LM; Helman LJ Oncogene; 2013 Nov; 32(47):5429-38. PubMed ID: 23318429 [TBL] [Abstract][Full Text] [Related]
23. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862 [TBL] [Abstract][Full Text] [Related]
24. Prostaglandin E Kim HB; Kim M; Park YS; Park I; Kim T; Yang SY; Cho CJ; Hwang D; Jung JH; Markowitz SD; Hwang SW; Yang SK; Lim DS; Myung SJ Gastroenterology; 2017 Feb; 152(3):616-630. PubMed ID: 27864128 [TBL] [Abstract][Full Text] [Related]
25. Two-signal requirement for growth-promoting function of Yap in hepatocytes. Su T; Bondar T; Zhou X; Zhang C; He H; Medzhitov R Elife; 2015 Feb; 4():. PubMed ID: 25667983 [TBL] [Abstract][Full Text] [Related]
26. NUAK2 is a critical YAP target in liver cancer. Yuan WC; Pepe-Mooney B; Galli GG; Dill MT; Huang HT; Hao M; Wang Y; Liang H; Calogero RA; Camargo FD Nat Commun; 2018 Nov; 9(1):4834. PubMed ID: 30446657 [TBL] [Abstract][Full Text] [Related]
27. miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. Diao Y; Guo X; Jiang L; Wang G; Zhang C; Wan J; Jin Y; Wu Z J Biol Chem; 2014 Jan; 289(1):529-39. PubMed ID: 24247238 [TBL] [Abstract][Full Text] [Related]
28. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430 [TBL] [Abstract][Full Text] [Related]
29. YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKɛ-mediated phosphorylation. Wang S; Xie F; Chu F; Zhang Z; Yang B; Dai T; Gao L; Wang L; Ling L; Jia J; van Dam H; Jin J; Zhang L; Zhou F Nat Immunol; 2017 Jul; 18(7):733-743. PubMed ID: 28481329 [TBL] [Abstract][Full Text] [Related]
30. Actin polymerization-enhancing drugs promote ovarian follicle growth mediated by the Hippo signaling effector YAP. Cheng Y; Feng Y; Jansson L; Sato Y; Deguchi M; Kawamura K; Hsueh AJ FASEB J; 2015 Jun; 29(6):2423-30. PubMed ID: 25690654 [TBL] [Abstract][Full Text] [Related]
31. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma. Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678 [TBL] [Abstract][Full Text] [Related]
32. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360 [TBL] [Abstract][Full Text] [Related]
33. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574 [TBL] [Abstract][Full Text] [Related]
35. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation. Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816 [TBL] [Abstract][Full Text] [Related]
36. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2. Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470 [TBL] [Abstract][Full Text] [Related]
37. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma. Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593 [TBL] [Abstract][Full Text] [Related]